Immunotherapy Treatment for Triple Negative Breast Cancer

• Hauptverfasser: Elizabeth R. Berger (VerfasserIn), Tristen Park (VerfasserIn), Angeleke Saridakis (VerfasserIn), Mehra Golshan (VerfasserIn), Rachel A. Greenup (VerfasserIn), Nita Ahuja (VerfasserIn)
• Format: Buch
• Veröffentlicht: MDPI AG, 2021-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the early breast cancer setting can be upwards to 72% in 5 years, and in the metastatic setting, the 5-year overall survival...